Aethlon Medical to Present at International Dialysis Conference.

Business Editors/Health/Medical Writers

LA JOLLA, Calif.--(BUSINESS WIRE)--Jan. 27, 2004

Aethlon Medical, Inc. (OTCBB:AEMD) announced that it will be a featured presenter at the "6th International Conference on Dialysis" which starts tomorrow in Rio Grande, Puerto Rico.

Aethlon's Chief Scientific Officer, Dr. Richard Tullis, will discuss the biological mechanisms that cause the transition from HIV infection to AIDS, and how Aethlon's HIV-Hemopurifier(TM) could be implemented to reduce viral load and curb T-Cell depletion. Dr. Tullis will also review the targeted use of the Hemopurifier(TM) as a treatment for Hepatitis-C, and other infectious diseases. The Aethlon presentation begins at 5pm on Thursday the 29th.

The conference is being sponsored by Fresenius Medical Care, and is endorsed by The American Society of Nephrology (ASN), the International Society of Nephrology (ISN), the National Kidney Foundation (NKF), the Renal Physicians Association (RPA), and the American Nephrology Nursing Association (ANNA).

About Aethlon Medical

Aethlon Medical is pioneering the development of viral filtration devices that reduce the presence of infectious disease and toxins in the body. To date, the Company has published pre-clinical results of its Hemopurifier(TM) to treat HIV/AIDS, and Hepatitis-C (HCV). The HIV-Hemopurifier removed 55% of HIV from human blood in three hours, and in excess of 85% in twelve hours. The HIV-Hemopurifier also cleared 90% of toxic proteins (gp-120) known to deplete immune cells in one hour. The HCV-Hemopurifier was documented to remove 58% of the Hepatitis-C virus from infected blood in two hours. The Hemopurifier(TM) is a proprietary platform technology that converges the established principles of affinity chromatography and hemodialysis as a means to augment the immune response of clearing viruses and toxins from human blood before cell and organ infection can occur. For additional information, visit the company's Web site at www.AethlonMedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.